Oral venetoclax plus IV obinutuzumab after prior CLL treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic lymphocytic leukemia (CLL) and it’s at the stage that needs treatment.
- You already had a fixed course of venetoclax plus an anti-CD20 antibody (with or without another drug).
- Your first treatment worked, based on your prior response being documented (types of remission/partial remission).
- Your CLL came back after a time gap: either over 24 months, or between 12 and 24 months (depending on the study group).
- You did not receive any other CLL treatment in between finishing that first venetoclax + anti-CD20 course and your current return of CLL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
This trial tests a combination of three drugs—roginolisib, obinutuzumab, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to previous treatment. The goal is to see if this combination can help control the disease.
This Phase 2 study tests how well zanubrutinib (a targeted pill) combined with venetoclax (another targeted pill) works for adults with CLL/SLL that came back or progressed after prior treatment. It may help by stopping cancer cells through two different pathways, aiming to shrink disease and improve blood counts.
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.